UCB Sa operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares UCB Sa with three other
pharmaceutical manufacturers in Europe:
Protek PAO
of Russia
(2018
sales of 251.73 billion Russian Rubles [US$3.97 billion]
of which 72%
was Distribution),
Grifols SA
of Spain
(4.49 billion Euro [US$4.99 billion]
of which 78%
was Bioscience), and
Lonza Group AG
which is
based in Switzerland
(5.54 billion Swiss Francs [US$5.64 billion]
of which 56%
was Pharma&Biotech).
Sales Analysis.
UCB Sa reported sales of 4.63 billion Euro (US$5.15 billion)
for the
year ending
December of 2018.
This
represents
an
increase of 2.3%
versus 2017, when the company's sales were 4.53 billion Euro.
This was the fourth straight year of sales growth at UCB Sa.